Rambaldi, Alessandro http://orcid.org/0000-0002-3739-7502
Iurlo, Alessandra http://orcid.org/0000-0002-4401-0812
Vannucchi, Alessandro M. http://orcid.org/0000-0001-5755-0730
Martino, Bruno
Guarini, Attilio
Ruggeri, Marco
von Bubnoff, Nikolas http://orcid.org/0000-0001-9593-8947
De Muro, Marianna
McMullin, Mary Frances http://orcid.org/0000-0002-0773-0204
Luciani, Stefania
Martinelli, Vincenzo
Nogai, Axel
Rosti, Vittorio
Ricco, Alessandra
Bettica, Paolo
Manzoni, Sara
Di Tollo, Silvia
Article History
Received: 17 November 2020
Revised: 18 February 2021
Accepted: 19 February 2021
First Online: 6 March 2021
Conflict of interest
: A.Ra. has received honoraria for consultancy, and travel support from Italfarmaco S.p.A., Gilead, Amgen, Novartis, Pfizer, Celgene, Sanofi, Astellas, and Roche. A.I. has received speaker honoraria from Novartis, Pfizer, Incyte, BMS, and Celgene. A.M.V. has received honoraria for advisory board participation from Novartis, Celgene, Incyte, CTI, and Italfarmaco, and for lectures from Novartis, and CTI. B.M. has no conflicts to disclose. A.G. has no conflicts to disclose. M.R. has no conflicts to disclose. N.v.B. received research funding from Novartis. M.D.M. has no conflicts to disclose. M.F.M. has received honoraria and has attended advisory boards with Novartis, Astellas, and Italfarmaco, and has received honoraria from Celgene. S.L. has no conflicts to disclose. V.M. has no conflicts to disclose. A.N. has received travel grants from Celgene and Takeda, and has attended advisory boards with Celgene, Takeda, Sanofi, Janssen, and Alexion. V.R. has no conflicts to disclose. A.Ri. has received honoraria for advisory board participation from Novartis, Alexion, and Sanofi. P.B., S.M., and S.D.T are employees of Italfarmaco SpA, the sponsor of the study.